SPX-1009 / Axim Biotech - LARVOL DELTA

AXIM Biotechnologies Completes Pre-Clinical Drug Studies on SPX-1009 Compound Proving Suppression of Melanoma Cells (GlobeNewswire) - "AXIM® Biotechnologies, Inc...announced...that it has completed pre-clinical drug studies on its patent pending compound SPX-1009, demonstrating the suppression of malignant metastatic melanoma cells...SPX-1009 was first screened in a cell-free enzymatic assay for its ability to inhibit Quiescin Sulfhydryl Oxidase....and was then tested for its ability to inhibit growth and invasion of a well-established A375 melanoma cell line and a low-passage patient-derived melanoma."

Preclinical • Melanoma • Oncology

AXIM Biotechnologies begins pre-clinical pharmacokinetic animal drug studies on its cancer drug compound SPX-1009 (GlobeNewswire) - "AXIM® Biotechnologies, Inc...announced...that its subsidiary Sapphire Biotech, Inc. ('Sapphire') has started pre-clinical animal drug studies on its new compound, SPX-1009...Sapphire scientists have generated and tested over 90 analogs of SBI-183 and discovered that one analog, SPX-1009, was tenfold more potent than SBI-183 in suppressing tumor invasion and metastasis in vitro. Further testing revealed that SPX-1009 suppressed invasion of breast, kidney and pancreas tumor cells in 2D and 3D invasion assays at tenfold lower concentrations than the parent compound SBI-183."

Preclinical • Breast Cancer • Oncology • Pancreatic Cancer • Renal Cell Carcinoma

Newly added product (GlobeNewswire) - Preclinical, Oncology, TNBC

Pipeline update